Drugs / BY101298
BY101298
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06462716 | Apr 2023 → Dec 2024 | cancer | Chengdu Baiyu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07226986 | Dec 2025 → Jul 2028 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06524804 | May → Oct 2024 | cancer | Chengdu Baiyu Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BY101298 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462716 ↗ |
| Known as | AMO959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226986 ↗ |
| Known as | BY1298 | “Subjects will receive a starting dose of 50 milligram (mg) of BY1298 as Capsule orally once daily, ascending to 100, 200, 300 and 400 mg.” NCT06462716 ↗ |
| Action | Inhibit | “An oral DNA-PK Inhibitor” NCT06462716 ↗ |
| Modality | Small molecule | “BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor.” NCT06462716 ↗ |
| Route | Oral | “Capsule orally once daily” NCT06462716 ↗ |